Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment.
about
Radiogenomic Analysis of Oncological Data: A Technical Survey.A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition.Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis.Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer
P2860
Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Radiogenomics Monitoring in Br ...... to Anti-angiogenic Treatment.
@en
Radiogenomics Monitoring in Br ...... to Anti-angiogenic Treatment.
@nl
type
label
Radiogenomics Monitoring in Br ...... to Anti-angiogenic Treatment.
@en
Radiogenomics Monitoring in Br ...... to Anti-angiogenic Treatment.
@nl
prefLabel
Radiogenomics Monitoring in Br ...... to Anti-angiogenic Treatment.
@en
Radiogenomics Monitoring in Br ...... to Anti-angiogenic Treatment.
@nl
P2093
P2860
P1433
P1476
Radiogenomics Monitoring in Br ...... to Anti-angiogenic Treatment.
@en
P2093
Adrian Jubb
Andreas Makris
Anwar Padhani
Francesca M Buffa
Lefteris Koumakis
Nick P Hughes
Rosie Adams
Ruud van Stiphout
Shaveta Mehta
Simon Lord
P2860
P304
P356
10.1016/J.EBIOM.2016.07.017
P577
2016-07-16T00:00:00Z